Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives $5.43 Average Target Price from Brokerages

Akoya Biosciences, Inc. (NASDAQ:AKYAGet Free Report) has been given a consensus recommendation of “Hold” by the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $5.43.

Several research analysts have recently commented on AKYA shares. Craig Hallum lowered Akoya Biosciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $7.00 to $5.00 in a research report on Friday, November 15th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 target price (down previously from $4.00) on shares of Akoya Biosciences in a research report on Tuesday, November 19th. Finally, Canaccord Genuity Group lowered Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th.

View Our Latest Report on AKYA

Akoya Biosciences Price Performance

Shares of NASDAQ AKYA opened at $3.07 on Friday. Akoya Biosciences has a fifty-two week low of $1.88 and a fifty-two week high of $6.31. The business has a 50 day moving average price of $2.46 and a two-hundred day moving average price of $2.59. The company has a quick ratio of 1.85, a current ratio of 2.75 and a debt-to-equity ratio of 5.62. The firm has a market cap of $152.18 million, a PE ratio of -2.60 and a beta of 1.18.

Institutional Investors Weigh In On Akoya Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Akoya Biosciences during the fourth quarter valued at $28,000. Regal Investment Advisors LLC raised its position in Akoya Biosciences by 64.3% during the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock valued at $44,000 after buying an additional 7,340 shares during the period. Barclays PLC raised its position in Akoya Biosciences by 320.9% during the third quarter. Barclays PLC now owns 39,472 shares of the company’s stock valued at $107,000 after buying an additional 30,095 shares during the period. Bank of New York Mellon Corp raised its position in Akoya Biosciences by 16.2% during the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after buying an additional 9,429 shares during the period. Finally, GSA Capital Partners LLP raised its position in Akoya Biosciences by 87.4% during the third quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after buying an additional 144,903 shares during the period. 79.42% of the stock is owned by institutional investors and hedge funds.

About Akoya Biosciences

(Get Free Report

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.

Featured Stories

Analyst Recommendations for Akoya Biosciences (NASDAQ:AKYA)

Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.